HIV Returns in Patients Thought Cured

The virus is back in two patients in Boston who received bone-marrow transplants and did not have detectable levels of virus for months.

By | December 10, 2013


Physician-scientists reported in July that two male patients had stopped anti-retroviral therapy and were HIV-free after bone-marrow transplants that occurred in 2008 in one man and 2010 in the second. Now, the scientists have announced that HIV is back in both patients.

“It’s disappointing and very sobering,” virologist Deborah Persaud of the Johns Hopkins Children’s Center in Baltimore, Maryland, told Nature News.

The men were given high-risk bone-marrow transplants to treat blood cancer and had no detectable levels of HIV in their blood eight months post-transplant. They each stopped taking anti-retroviral drugs earlier this year and did not test positive for HIV for months. Timothy Henrich of Brigham and Women’s Hospital in Boston, one of the patients’ physicians, said today in a statement that one man’s HIV returned in August and the second man’s blood tested positive in November. Both men are now back on anti-retroviral drugs and doing fine, and in the statement, Henrich acknowledged “their commitment to research.” He added that the reappearance of the virus demonstrates that “there may be an important long-lived HIV reservoir outside the blood compartment.”

Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, told The New York Times that the return of HIV in the men “doesn’t put an end to this avenue of research, but it certainly does put a damper on it.”

“The failure to cure these individuals will certainly influence the conduct of future clinical trials,” Steven Deeks, an HIV researcher and physician at the University of California, San Francisco, told Nature News. “It is now clear viral rebounds can happen at any time, even months after stopping therapy. People will have to followed very carefully for more prolonged periods than in the past.”

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo


Avatar of: LeeH


Posts: 35

December 10, 2013

This outcome should have have come as much of a surprise.  The liklihood of eradication is relatively small given that, at least, part of the viral reservoir is dormant at any point in time.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham